SYROS PHARMACEUTICALS INC (SYRS)
US87184Q2066 - Common Stock
Taking everything into account, SYRS scores 2 out of 10 in our fundamental rating. SYRS was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of SYRS have multiple concerns. SYRS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SYRS had negative earnings in the past year.
In the past year SYRS has reported a negative cash flow from operations.
In the past 5 years SYRS always reported negative net income.
In the past 5 years SYRS always reported negative operating cash flow.
1.2 Ratios
SYRS's Return On Assets of -97.86% is on the low side compared to the rest of the industry. SYRS is outperformed by 77.30% of its industry peers.
Looking at the Return On Equity, with a value of -987.72%, SYRS is doing worse than 83.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.86% | ||
| ROE | -987.72% | ||
| ROIC | N/A |
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SYRS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
SYRS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SYRS has been increased compared to 5 years ago.
Compared to 1 year ago, SYRS has a worse debt to assets ratio.
2.2 Solvency
SYRS has an Altman-Z score of -7.10. This is a bad value and indicates that SYRS is not financially healthy and even has some risk of bankruptcy.
SYRS has a Altman-Z score of -7.10. This is in the lower half of the industry: SYRS underperforms 70.99% of its industry peers.
SYRS has a Debt/Equity ratio of 2.07. This is a high value indicating a heavy dependency on external financing.
SYRS has a worse Debt to Equity ratio (2.07) than 81.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.1 |
ROIC/WACCN/A
WACC9.16%
2.3 Liquidity
A Current Ratio of 3.95 indicates that SYRS has no problem at all paying its short term obligations.
SYRS has a Current ratio (3.95) which is comparable to the rest of the industry.
A Quick Ratio of 3.95 indicates that SYRS has no problem at all paying its short term obligations.
SYRS's Quick ratio of 3.95 is in line compared to the rest of the industry. SYRS outperforms 45.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.95 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
SYRS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.93%, which is quite impressive.
Looking at the last year, SYRS shows a very negative growth in Revenue. The Revenue has decreased by -33.34% in the last year.
Measured over the past years, SYRS shows a very strong growth in Revenue. The Revenue has been growing by 37.12% on average per year.
EPS 1Y (TTM)54.93%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1182.35%
Revenue 1Y (TTM)-33.34%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Revenue growth Q2Q151.47%
3.2 Future
Based on estimates for the next years, SYRS will show a very strong growth in Earnings Per Share. The EPS will grow by 37.06% on average per year.
SYRS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 137.81% yearly.
EPS Next Y34.69%
EPS Next 2Y18.65%
EPS Next 3Y20.53%
EPS Next 5Y37.06%
Revenue Next Year-75.69%
Revenue Next 2Y66.88%
Revenue Next 3Y135.87%
Revenue Next 5Y137.81%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
SYRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SYRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SYRS's earnings are expected to grow with 20.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.65%
EPS Next 3Y20.53%
5. Dividend
5.1 Amount
SYRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SYROS PHARMACEUTICALS INC
NASDAQ:SYRS (5/2/2024, 7:21:36 PM)
After market: 5.2 0 (0%)5.2
-0.24 (-4.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap137.54M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -97.86% | ||
| ROE | -987.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.95 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)54.93%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-33.34%
Revenue growth 3Y-13%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y